Less talk and more action on U.S. prescription drug pricing is the message coming from Capitol Hill as the number of bills addressing prices is escalating while the number of lawmakers showing up for hearings on the issue is declining. Read More
Comet Therapeutics Inc., a startup working to build a portfolio of therapies for restoring dysregulated coenzyme A metabolism, has raised $28.5 million in series A financing co-led by Canaan Partners and Sofinnova Partners. Read More
Denovo Biopharma LLC has licensed ORM-12741 from Orion Corp., along with global rights to develop, manufacture and commercialize the alpha-2c adrenoceptor antagonist that has failed several previous clinical trials. Read More
As the weekend PDUFA date for bremelanotide approaches, investors in Waltham, Mass.-based Amag Pharmaceuticals Inc. hope an approval will revive the stock, on the slide since last summer. Generating interest at the same time, though, is ciraparantag, brought in-house via the buyout in December of Perosphere Pharmaceuticals Inc., of Danbury, Conn. Read More
Singapore-based Tessa Therapeutics Ltd. and China-Singapore Guangzhou Knowledge City are committing a combined $120 million to establish a joint venture to advance cell therapies targeting prevalent cancers in China. Read More
Proteona Pte. Ltd., of Singapore, has launched the first commercial product designed to characterize both RNA and protein expression levels across thousands of single chimeric antigen receptor T cells. Read More
Catalent Inc., of Somerset, N.J., said it agreed to purchase the oral solid, biologics and sterile product manufacturing and packaging facility in Anagni, Italy, owned by Bristol-Myers Squibb Co., of New York. Read More
Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it closed an underwritten public offering of 8 million common shares priced at 75 cents apiece, including 4 million shares that were placed with John Kim Scott, Jr., a principal stockholder, at the public offering price. Read More
Unum Therapeutics Inc., of Cambridge, Mass., appointed Matthew Osborne chief financial officer, effective June 24, Jessica Sachs chief medical officer, effective July 15, and Mert Aktar head of business and corporate development. Read More
